title: Update on ankylosing spondylitis: current concepts in pathogenesis.
abstract: Ankylosing spondylitis is an insidiously progressive and debilitating form of arthritis involving the axial skeleton. The long delay in diagnosis and insufficient response to currently available therapeutics both advocate for a greater understanding of disease pathogenesis. Genome-wide association studies of this highly genetic disease have implicated specific immune pathways, including the interleukin (IL)-17/IL-23 pathway, control of nuclear factor kappa B (NF-κB) activation, amino acid trimming for major histocompatibility complex (MHC) antigen presentation, and other genes controlling CD8 and CD4 T cell subsets. The relevance of these pathways has borne out in animal and human subject studies, in particular, the response to novel therapeutic agents. Genetics and the findings of autoantibodies in ankylosing spondylitis revisit the question of autoimmune vs. autoinflammatory etiology. As environmental partners to genetics, recent attention has focused on the roles of microbiota and biomechanical stress in initiating and perpetuating inflammation. Herein, we review these current developments in the investigation of ankylosing spondylitis pathogenesis.
authors.affiliation: Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, School of Medicine and Public Health, University of Wisconsin-Madison, 600 Highland Ave, H4/472 CSC, Madison, WI, 53709-4108, USA, jsmith27@pediatrics.wisc.edu.
authors.forename: Judith A
authors.initials: JA
authors.lastname: Smith
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000235:genetics / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes; D020022:Genetic Predisposition to Disease; D006801:Humans; D020381:Interleukin-17 / Q000276:immunology; D053759:Interleukin-23 / Q000276:immunology; D013167:Spondylitis, Ankylosing / Q000235:genetics / Q000276:immunology* / Q000382:microbiology / Q000628:therapy
chemical_list: D020381:Interleukin-17; D053759:Interleukin-23